

## PAPERS

1. **Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, for the ALLHAT Research Group. *Am J Hypertension* 1996; 9 (Part 1):342-360. (Paper Not Numbered)
2. **Experimental approaches to determining the choice of first step therapy for patients with hypertension.** Whelton PK, Williamson JD, Louis GT, Davis BR, Cutler JA, for the ALLHAT Research Group. *Clinical and Experimental Hypertension* 1996; 18:569-579. (Paper Not Numbered)
3. **Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.** Vidt DG. *Cleveland Clinic J Medicine* 2000; 67:429-433. (Paper 18) June
4. **Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *JAMA* 2000;283:1967-1975. (Paper 16)
5. **Baseline characteristics of the 42,448 high risk hypertensives enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Eckfeldt J, Hawkins CM, Proschan M, for the ALLHAT Collaborative Research Group. *Hypertension* 2001; 37:19-27. (Paper 3)
6. **Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD, for the ALLHAT Collaborative Research Group. *Controlled Clinical Trials* 2001; 22:29-41. (Paper 17)
7. **Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS, for the ALLHAT Collaborative Research Group. *Diabetes Care* 2001; 24:654-658. (Paper 14)
8. **First results from ALLHAT: Implications for management of urban hypertensives.** Kumar A, Wright JT, Haywood LJ. *ABC Digest of Urban Cardiology* 2001; 8: 21-24. (Paper 25)
9. **Status of alpha-blocker therapy in the treatment of hypertension: Findings of ALLHAT.** Furberg CD, Cutler JA, Davis BR. *Harrison's Online* ([http://harrisonsonline.com/server-java/Arknoid/amed/harrisons/ex\\_editorials/edl2856\\_p01.html](http://harrisonsonline.com/server-java/Arknoid/amed/harrisons/ex_editorials/edl2856_p01.html)) September 19, 2001. (Paper 26)
10. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience.** Wright JT, Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FHH, Frolkis J, Letterer R, Walsh S, Tobin JN, Deger GE, for the ALLHAT Research Group. *Controlled Clinical Trials* 2001; 22:659-673. (Paper 2)
11. **Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H, for the ALLHAT Research Group. *Controlled Clinical Trials* 2001; 22:674-686. (Paper 1)
12. **Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD, for the ALLHAT Collaborative Research Group. *Ann Intern Med* 2002; 137:313-320. (Paper 19)
13. **Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone.** Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Jr, Williamson JD, Leenen FHH, Einhorn PT, Randall OS, Golden JS, Haywood LJ, for the ALLHAT Collaborative Research Group. *Current Controlled Trials in Cardiovascular Medicine* 2002; 3:10-18. (Paper 20) On-line at the following URL, last accessed on March 31, 2003: <http://cvm.controlled-trials.com/content/3/1/10>.
14. **Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium**

- channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *JAMA* 2002; 288:2981-2997. (Paper 31) **Correction of Table 6:** *JAMA* 2003; 289:178.
15. **Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).** The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *JAMA* 2002; 288:2998-3007. (Paper 32)
  16. **Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2002; 4:393-404. (Paper 11)
  17. **The ANBP2 and ALLHAT: Conflicting or consistent?** Cutler JA. *J Clin Hypertens* 2003; 5:192-195. (Paper 63)
  18. **Diuretic versus -blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. *Hypertension* 2003; 42:239-246. (Paper 23)
  19. **Characteristics and lipid distribution of a large, high-risk, hypertensive population: The lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reison E, Sumner BM, Wong ND, Nwachuku C, Narayan P, Haywood LJ, Habib G, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2003; 5:377-385. (Paper 8)
  20. **What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.** Geraci TS, Geraci SA. *J Cardiovascular Nursing* 2003; 18:389-395. (Paper 66)
  21. **Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: A report from the ALLHAT study.** Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2004; 6:116-125. (Paper 21)
  22. **The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease. A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C, for the ALLHAT Collaborative Research Group. *Arch Intern Med* 2004; 164:969-976. (Paper 13)
  23. **ALLHAT: Setting the record straight.** Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P. *Ann Intern Med* 2004; 141:39-46. (Paper 74)
  24. **ALLHAT: What has it taught us so far?** Leenen FHH. *Canadian Medical Assoc J* 2004; 171:719-720. (ALLHAT Related Commentary)
  25. **The ALLHAT Adherence Survival Kit.** Lusk CM, Bettencourt J, Carroll L, Egan D, Ford CE, Kingry C, Johnason J, Sullivan S, Nwachuku C, Probstfield JL. *Applied Clinical Trials* 2004; 13:40-48. (Paper 10)
  26. **Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.** Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FHH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB, for the ALLHAT Collaborative Research Group. *JAMA* 2005; 293:1595-1608. (Paper 37)
  27. **Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Rahman M, Pressel S, Davis B, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, for the ALLHAT Collaborative Research Group. *Arch Intern Med* 2005; 165:936-946. (Paper 43)
  28. **Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia.** Whelton PK, Barzilay J, Cushman WC, Davis BR, Ilamathi E, Kostis JB, Leenen FHH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D,

- Parish DC, Pressel S, Simmons DL, Thadani U, for the ALLHAT Collaborative Research Group. *Archives of Internal Medicine* 2005; 165:1401-1409. (Paper 38)
29. **Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.** Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr, Whelton P, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, for the ALLHAT Collaborative Research Group. *Annals of Internal Medicine* 2006; 144:172-180. (Paper 73)
30. **The role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, for the ALLHAT Collaborative Research Group. *Circulation* 2006; 113:2201-2210. (Paper 46)
31. **Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Leenen FHH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZA, Proschan MA, Thadani U, Whelton PK, Wright JT; for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. *Hypertension* 2006;48:374-384. (Paper 78)
32. **Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2006; 8:649-656. (Paper 22)
33. **Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment.** Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, for the ALLHAT Collaborative Research Group. *Arch Intern Med* 2006; 166:2191-2201. (Paper 28)
34. **The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure validation study: Diagnosis and prognosis.** Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR, for the ALLHAT Collaborative Research Group. *Am Heart J* 2007; 153:42-53. (Paper 56)
35. **Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, Colon PJ Sr, Vidt DG, Christian R, Wong ND, Wright JT Jr, Goff DC Jr, and ALLHAT Collaborative Research Group. *Hypertension* 2007; 50:854-861. (Paper 12)
36. **Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZA, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, Davis BR. *Arch Intern Med* 2008;168:207-217. (Paper 91)
37. **Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: An analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Lee Goldman L. *J General Internal Medicine* 2008; 23:509-516. (Paper 33)
38. **Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension. A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT Jr, Basile J, Wong ND, Whelton P, Dart RA, Thadani U. *Diabetes Care* 2008; 31:353-360. (Paper 48)
39. **Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.** Cutler JA, Davis BR. *Circulation* 2008; 117:2691-2705. (Paper 109)
40. **Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart**

- Attack Trial (ALLHAT).** Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasin S, Stanford C, on behalf of the ALLHAT Collaborative Research Group. *Am J Kidney Dis* 2008; 52:412-424. (Paper 82)
41. **Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC, Ford CE, Einhorn PT, Wright JT, Preston RA, Davis BR, Basile JN, Whelton PK, Weiss RJ, Bastien A, Courtney DL, Hamilton BP, Kirchner K, Louis GT, Retta TM, Vidt DG, for the ALLHAT Collaborative Research Group. *J Clin Hypertens* 2008; 10:751-760. (Paper 47)
42. **Heart failure with preserved and reduced left ventricular ejection fraction in ALLHAT.** Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Shah Nawaz S, for the ALLHAT Collaborative Research Group. *Circulation* 2008; 118:2259-2267. (Paper 52)
43. **Management of high blood pressure in clinical practice: Perceptible qualitative differences in approaches utilized by clinicians.** Nwachuku C, Bastien A, Cutler J, Grob G, Margolis K, Roccella E, Pressel S, Davis B, Caso M, Sheps S, Weber M. *J Clin Hypertens* 2008; 10:822-829. (Paper 67)
44. **Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines.** Muntner P, Krousel-Wood M, Hyre AD, Stanley E, Cushman WC, Cutler JA, Piller LB, Goforth GA, Whelton PK. *Hypertension* 2009; 53:617-623. (Paper 110)
45. **ALLHAT findings revisited in the context of subsequent analyses, other trials and meta-analyses.** Wright JT Jr, Probstfield JL, Cushman WC, Pressel S, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, for the ALLHAT Collaborative Research Group. *Archives Intern Med* 2009; 169:832-842. (Paper 92)
46. **Getting clinical trial results into practice: Design, implementation, and process evaluation of the ALLHAT Dissemination Project.** Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Graumlich JF, Piller LB, Pressel S, Roccella EJ, Simpson L, Whelton PK, Williard A, for the ALLHAT Collaborative Research Group. *Clinical Trials* 2009; 6:329-343. (Paper 93)
47. **Heart failure in ALLHAT: Did blood pressure medication at study entry influence outcome?** Grimm RH, Davis BR, Piller LB, Cutler JA, Margolis KL, Barzilay J, Dart RA, Graumlich JF, Murden RA, Randall OS, for the ALLHAT Collaborative Research Group. *J Clin Hypertens (Greenwich)* 2009; 11:466-474. (Paper 59)

#### ANCILLARY STUDIES

- 1. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.** Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. *The Pharmacogenomics Journal* 2002; 2:309-317. (Paper 54)
- 2. Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses - A new method for the Genetics of Hypertension Associated Treatment (GenHAT) Study.** Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. *Statistics in Medicine* 2004; 23:2413-2427. (Paper 57)
- 3. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study.** Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. *Circulation* 2005; 111:3374-3383. (Paper 58)
- 4. Absence of an interaction between the angiotensin converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) Study.** Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH. *Am Heart J* 2007; 153:54-58. (Paper 79)
- 5. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: The Genetics of Hypertension-Associated Treatment Study.** Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. *The*

*Pharmacogenomics Journal* 2007; 7:112-122.  
(Paper 68)

6. **Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: The GenHAT study.** Lynch AI, Arnett DK, Davis BR, Boerwinkle E, Ford CE, Eckfeldt JH, Leidecker-Foster C. *Annals of Human Genetics* 2007; 71:735–745. (Paper 83)
7. **Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.** Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leidecker-Foster C, Arnett DK. *JAMA* 2008; 299:296-307. (Paper 94)
8. **Interactions between the SNPs in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk hypertensives: The GenHAT Study.** Maitland-van der Zee AH, Lynch A, Boerwinkle E, Arnett DK, Davis BR, Leidecker-Foster C, Miller MB, Ford CE, Eckfeldt JH. *Pharmacogenetics and Genomics* 2008; 18:651-656. (Paper 116)
9. **The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.** Maitland-van der Zee AH, Peters BJ, Lynch AI, Boerwinkle E, Arnett DK, Cheng S, Davis BR, Leidecker-Foster C, Ford CE, Eckfeldt JH. *Pharmacogenetics and Genomics* 2009; 19:338–344. (Paper 123)
10. **Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.** Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leidecker-Foster C, Arnett DK. *Pharmacogenetics and Genomics* 2009; (In Press) (Paper 117)

#### BOOK CHAPTERS

1. **Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cutler JA, Gordon DJ, Davis BR, Wright JT, Furberg CD. In: Black HR, ed. *Clinical Trials in Hypertension*, New York, NY: Marcel Dekker; 2001: 531-586. (Paper 9)
2. **Data monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Davis BR, Cutler JA. In: *Data Monitoring in Clinical Trials: A Case*

*Studies Approach*, DeMets DL, Furberg CD, Friedman L, eds. Springer, 2005:248-259.  
(Paper 75)

3. **JNC 7 and ALLHAT - An Insider's View.** Cushman WC. In: *Atlas of Hypertension* (Chapter 16), 5<sup>th</sup> Edition, Hollenberg N, ed. Current Medicine, LLC, Philadelphia, PA, 2005: 363-377. (Paper 80)
4. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Wright JT, Oparil S. In: *Hypertension: A Companion to Brenner and Rector's The Kidney* (Chapter 30), 2<sup>nd</sup> Edition, Oparil S, Weber MA, ed. Elsevier, Inc., Philadelphia, PA, 2005: 340-351. (Paper 76)

#### LETTERS

1. **ALLHAT and calcium channel blockers.** Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R, Oparil S, for the ALLHAT Research Group. *Am J Hypertension* 1997; 10:142-143.
2. **Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.** Letters to the Editor. Wright JT Jr, Davis BR, Cutler JA, for the ALLHAT Collaborative Research Group. *JAMA* 2003; 289: 2066-2070.
3. **Angiotensin-converting-enzyme inhibitors and diuretics for hypertension.** Davis BR, Wright JT, Jr., Cutler JA. *N Engl J Med* 2003; 349:91-92.
4. **Angiotensin-converting enzyme inhibitors and diuretics: Optimal combination therapy.** Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P. *Annals of Internal Medicine* 2004; 141:893. (Paper 74)
5. **Omission of Drug Dose Information.** Rahman M, Pressel S, Davis BR. *Arch Intern Med* 2006; 166:368-369. (Feb. 13.) (Paper 43)
6. **Re: Hawkins RG, Houston MC. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis.** *Am J Hypertens* 2005; Jun;18(6):744-9. Rahman M, Nwachuku C, Whelton P, Probstfield J, Davis BR. *Am J Hypertension* 2006; 19:656-657. (Paper 43)
7. **Response to Letter Regarding Article, "Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)".** Davis BR, Piller LB, Dunn K, Cutler JA, Proschan M, Furberg C, Goff

- D, Franklin S, Leenen F, Mohiuddin S, Papademetriou V, Ellsworth A, Golden J, Colon P, Crow R. *Circulation* 2007;115:19-19. (Paper 95)
8. **Re: Messerli FH, Bangalore S, Julius S. Risk/Benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension.** Cutler JA, Davis BR. *Circulation* 2008; 117:2715-2715. (Related to Paper 109)
9. **Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension.** Davis BR, Whelton PK, for the ALLHAT Research Group. *NEJM* 2009; 360: 1147-1150. (Response to ACCOMPLISH)
10. **ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.** Wright JT Jr, Probstfield JL, Cushman WC, Pressel S, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, for the ALLHAT Collaborative Research Group. *Arch Intern Med* 2009; 169:1810-1811. (Paper 92, Response to Onuigbo Letter)

#### ALLHAT RELATED PAPERS

- Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials.** Blood Pressure Lowering Treatment Trials' Collaboration. *Arch Intern Med* 2005; 165:1410-1419. (ALLHAT Related Paper)
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statin.** Cholesterol Treatment Trialists' (CTT) Collaborators. *Lancet* 2005; 366:1267-78. (Paper 88)
- Antihypertensive medications and risk of diabetes mellitus.** Barzilay JI, Cutler JA, Davis BR. *Current Opinion in Nephrology and Hypertension* 2007; 16:256-260. (Paper 98)
- Metabolic Consequences of Thiazide Diuretics for Hypertension. The latest from a post-hoc analysis of the ALLHAT Trial.** Barzilay JI, Cutler JA, Pressel SL, Davis BR. *Review of Endocrinology* 2007; 1:56-57. (Paper 102)

#### ABSTRACTS & PRESENTATIONS

- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial: Design features.** Davis B, for the ALLHAT Research Group. *Abstract: Controlled Clinical Trials* 1995; 16(3S):47S. (Presented at 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)
- Recruitment success by type of site in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Vanguard.** Egan D, Pressel S, Davis B, on behalf of the ALLHAT Research Group. *Abstract: Controlled Clinical Trials* 1995; 16(Suppl 3):106S. (Presented at the 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.) (Paper 1)
- Selection of Clinical Sites for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Pressel S, Egan D, Ford C, Walsh S, Miertschin N, on behalf of the ALLHAT Research Group. *Abstract: Controlled Clinical Trials* 1995; 16(3S):128S-129S. (Presented by Sara Pressel at 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.) (Paper 2)
- Workshop III - Operational perspectives in the conduct of large multicenter clinical trials.** Davis B, for the ALLHAT Research Group. *Abstract: Controlled Clinical Trials* 1995; 16(3S):14S-15S. (Presented at the 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April 30-May 3, 1995.)
- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Design and initial characteristics.** Cushman WC, for the ALLHAT Research Group. *Abstract: Hypertension* 1995; 25:1356. (Presented at the 11th Scientific meeting of the Inter-American Society of Hypertension; Montréal, Quebec; June 17-20, 1995.) (Paper 3)
- The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and early baseline results.** Grimm RH, Jr, for the ALLHAT Research Group. (Presented at the 11th Asian-Pacific Congress of Cardiology; Bali, Indonesia; September 17-22, 1995.) (Paper 3)
- Design and aims of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC. (Presented at the Panhellenic Congress on Arterial Hypertension; Greece, March 1, 1996.)
- ALLHAT invited presentation - "Equal risk for equal pressure?"** Cutler J, Furberg C, Temple R, DeMets D. (Presented at the Society for Clinical Trials Plenary Session; Pittsburgh, PA; May 6, 1996.)

9. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on recruitment and baseline characteristic.** Grimm RH, Jr, Davis B, Whelton P, Pressel S, for the ALLHAT Research Group. **Abstract:** *Am J Hypertension* 1996; 9 (Part II): 26A. (Presented at the 11th Scientific Meeting of the American Society of Hypertension: New York, NY; May 15-18, 1996.) (Paper 3)
10. **Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Whelton P. **Abstract:** *International Society of Hypertension book of abstracts*, June 1996.
11. **Patient recruitment experience in the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Whelton P, Cutler J, Davis B, Grimm R, Pressel S, Probstfield J, Ward H, for the ALLHAT Research Group. **Abstract:** *J Hypertension* 1996; (Suppl 1):998. (Presented at the 16th Scientific Meeting of the International Society of Hypertension; Glasgow, U.K.; June 23-27, 1996.) (Paper 1)
12. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Recruitment update and baseline data.** Wright JT, Jr, Cutler JA, Davis BR, Cushman WC, Pressel S, for the ALLHAT Research Group. **Abstract:** *Conference abstract monograph*. (Presented at the 11th International Interdisciplinary Conference on Hypertension in Blacks; New Orleans, LA; July 14-17 1996.)
13. **Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments.** Davis B, Proschan M, Ford CE, for the ALLHAT Research Group. (Presented at the *International Biometric Conference*; Amsterdam, Netherlands; July 1-5, 1996.)
14. **Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments.** Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group. (Presented at the *American Statistical Association Meeting*; Chicago, IL; August 4-18, 1996.)
15. **Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on Southeastern Clinical Research.** Cushman WC. (Presented at the 3rd Annual Meeting of the Consortium of Southeastern Hypertension Centers; Research Triangle Park, NC; August 15, 1996.)
16. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design, recruitment experience and baseline characteristics.** Papademetriou V, Grimm KH, Jr, for the ALLHAT Research Group. **Abstract:** ????. (Presented at the 4th International Symposium on Multiple Risk Factors in Cardiovascular Disease; Washington, D.C.: April 23-25, 1997.) (Paper 3)
17. **Newer vs. older drugs  $\pm$  cholesterol lowering: ALLHAT.** Cutler J. (Presented at the WHO-ISH Collaboration Annual Meeting and Clinical Trials Symposium; St. Jean Cap Ferrat, France; May 1-3, 1997.) (No written material associated with this presentation.)
18. **Characteristics of the diabetic cohort in the ALLHAT study.** Barzilay J, Jordan J, Grimm R, Davis B, Oparil S, and the ALLHAT Investigators. **Abstract:** *Hypertension* 1997; 10:86A. (Presented at the 12th Scientific Meeting of the American Society of Hypertension; San Francisco, CA; May 28-31, 1997.) (Paper 14)
19. **The impact of external events on on-going clinical trials.** Davis BR, Sacks F, Alderman M, Thornquist M, DeMets DL. **Abstract:** *Controlled Clinical Trials* 1997; 18(3S):33S. (Presented at the 2nd Joint Meeting of the Society of Clinical Trials/International Society of Clinical Biostatistics; Boston, MA; July 6-10, 1997.)
20. **A clinical data comparison of African American and non-African American participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Brown N, Evans SA. **Abstract:** *Ethnicity and Disease* 1997; 7(Suppl):S25. (Presented at the 12th Interdisciplinary Conference on Hypertension in Blacks; London, England; July 20-24, 1997.)
21. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT.** Oparil S. **Abstract:** ????. (Presented at the 4th International Conference on Preventive Cardiology Satellite Symposium entitled, "Optimal Therapy in the Prevention of CAD"; Montreal, Quebec; June 29-July 3, 1997.)
22. **ALLHAT: The largest clinical trial in hypertension ever undertaken.** Davis BR, Hawkins CM, Cutler JA, Payne G, Ford CE, Pressel S, Gordon D, Nwachuku C, Wright J, Cushman W, Grimm R for the ALLHAT Research Group. (Presented by BR Davis at the 6th International Symposium on Hypertension in the Community: Screening, Investigation, and Therapy, February 8-11, 1998, Geneva, Switzerland.)
23. **Comparison among Puerto Rican, African American, and non-African American participants in the ALLHAT study.** Colon PJ

- Sr, Colon PJ Jr, Oparil S, Pressel S, Garcia-Palmieri MR. **Abstract:** *J Am College Cardiology* 1998; 31:463C. (Presented by Pedro Colon at the 13<sup>th</sup> World Congress of Cardiology, April 26-30, 1998, Rio De Janeiro, Brazil.)
24. **Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman WC, Black HR, Probstfield JL, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE, Payne GH, Ford CE for the ALLHAT Research Group. **Abstract:** *Am J Hypertension* 1998; 11:17A. (Presented by WC Cushman at the 13<sup>th</sup> Scientific Meeting of the American Society of Hypertension, May 13-16, 1998, New York, NY.) (**Paper 11**)
25. **Visit (Vad) and medication (Mad) adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Effect of age and other factors.** Nwachuku CE, Probstfield JL, Ford CE, Payne GH, Grimm RH for the ALLHAT Research Group. **Abstract:** *Am J Hypertension* 1998; 11(Suppl 1):82A. (Presented by CE Ford at the 13<sup>th</sup> Scientific Meeting of the American Society of Hypertension, May 13-16, 1998, New York, NY.) (**Paper 4**)
26. **Regional differences in attainment of goal blood pressure (BP) amongst United States (US) treated hypertensives in ALLHAT.** **Abstract:** *J Hypertension* 1998; 16 (Suppl 2):Abstract 97.6. (Presented by R Grimm at the 17<sup>th</sup> Scientific Meeting of the International Society of Hypertension, Amsterdam, Netherlands, June 6-11, 1998.) (**Paper 11**)
27. **Racial differences in blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Margolis KL, Cushman WC, Wright JT, Grimm RH, Ford CE, Cutler JA for the ALLHAT Research Group. **Abstract:** *J General Internal Medicine* 1999; 14(Suppl 2):52. (Presented by KL Margolis at the 22<sup>nd</sup> Annual Meeting of the Society for General Internal Medicine, San Francisco, California, April 30, 1999.) (**Paper 11**)
28. **ALLHAT Adherence Survival Kit.** Lusk CM, Egan D, Carroll L, Kingry C, Johnson JM, Sullivan S, Probstfield J for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. **Abstract:** *Controlled Clinical Trials* 1999; 20(2S):38S. (Presented by CM Lusk at the 20<sup>th</sup> Annual Meeting of the Society for Clinical Trials, Anaheim, CA, May 3, 1999.) (**Paper 10**)
29. **Atrial fibrillation in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) clinical trial at baseline.** Haywood LJ, Crow R, Ford C, for the ALLHAT Research Group. **Abstract:** *Ethnicity and Disease* 1999; 9:293. (Presented by LJ Haywood at the 14<sup>th</sup> International Interdisciplinary Conference on Hypertension in Blacks, Toronto, Ontario, Canada, July 10-14, 1999.) (**Paper 36**)
30. **Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: Preliminary results from ALLHAT.** The ALLHAT Collaborative Research Group. (Presented by C. Furberg and BR Davis at the 49<sup>th</sup> Annual Scientific Session of the American College of Cardiology, Late-Breaking Clinical Trials in Interventional Cardiology (#72), ANAHEIM, CA, March 15, 2000 [10:45 am-12:15 pm].) (**Final Paper 1**)
31. **ALLHAT Adherence Survival Kit.** Lusk CM, Egan D, Carroll L, Kingry C, Johnson JM, Sullivan S, Probstfield J. **Abstract:** *Controlled Clinical Trials* 2000; 21:52S-53S. (Presented by C. Lusk at the 21<sup>st</sup> Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.) (**Paper 10**)
32. **The role of the regional coordinator in clinical trials: Lessons learned.** Lucente T, Williard A, Hynes J, Johnson J, Kingry C, Letterer R, Pressel S, Ragusa P, Ross S. **Abstract:** *Controlled Clinical Trials* 2000; 21:60S-61S. (Presented by T. Lucente at the 21<sup>st</sup> Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.) (**Paper 6**)
33. **Clinical center recruitment experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Davis BR, Pressel S, Wright J, Cushman W, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Leenen F, Frolkis J, Letterer R, Walsh S, Tobin J, Deger G, for the ALLHAT Research Group. **Abstract:** *Controlled Clinical Trials* 2000; 21:63S-64S. (Presented by B. Davis at the 21<sup>st</sup> Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.) (**Paper 2**)
34. **Management of participant clinic transfers in a large simple trial – ALLHAT.** Lusk CM, Carroll L, Pressel S. **Abstract:** *Controlled Clinical Trials* 2000; 21:104S. (Presented by S. Pressel at the 21<sup>st</sup> Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
35. **The ascertainment of endpoints by primary care practitioners in a long-term clinical trial.** Piller L, Davis B, Kimmel B, Nwachuku C. **Abstract:** *Controlled Clinical Trials* 2000; 21:104S-105S. (Presented by L. Piller at the 21<sup>st</sup> Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)

36. **Using educational grants to improve adherence and retention in ALLHAT.** Kimmel B, Juratovac A, Ragusa P, Piller L, Pressel S, Barry A, Payne G. **Abstract:** *Controlled Clinical Trials* 2000; 21:105S. (Presented by B. Kimmel at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
37. **Differences in adherence patterns of ALLHAT participants.** Bettencourt J, Ford CE. **Abstract:** *Controlled Clinical Trials* 2000; 21:105S-106S. (Presented by J Bettencourt at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
38. **Quality control site visits in large, simple trials – The ALLHAT experience.** Pressel S, Lucente T, Carroll L, Bettencourt J. **Abstract:** *Controlled Clinical Trials* 2000; 21:120S-120S. (Presented by S. Pressel at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.)
39. **Cardiovascular disease rates in Hispanic and Caribbean hypertensives receiving doxazosin and chlorthalidone in the ALLHAT.** Colon PJ, Wright JT, Ford CE, Cuttler JA, for the ALLHAT Collaborative Research Group. **Abstract:** *Ethnicity and Disease* 2000; 10:315-316. (Presented by P. Colon at the Joint Meeting of the International Society for Hypertension in Blacks and the 15th Annual Interdisciplinary Conference on Hypertension and Related Risk Factors in Ethnic Populations, July 15-18, 2000, Las Croabas, Puerto Rico.) (Paper 12)
40. **Blood pressure control in Hispanic participants in ALLHAT.** Margolis K, Piller L, Lewis C, Goff D, Cushman W, Wright J, Colon P, Ford C. **Abstract:** *Circulation* 2001; 103:1348. (Presented by K. Margolis at the 41<sup>st</sup> AHA Conference on Cardiovascular Disease Epidemiology and Prevention, San Antonio, Texas, March 2, 2001.) (Paper 12)
41. **Validation of heart failure events in ALLHAT participants assigned to doxazosin and chlorthalidone.** Piller L, Davis B, Cutler J, Cushman W, Probstfield J, Williamson J, Leenen F, Randall O, Golden J, Wright J. **Abstract:** *Am J Hypertension* 2001; 14:180A. (Presented by L. Piller at the 16<sup>th</sup> Scientific Meeting of the American Society of Hypertension, San Francisco, California, May 2001.) (Paper 20)
42. **Practical issues in conducting multicenter clinical trials.** Pressel S. **Abstract:** *Controlled Clinical Trials* 2001; 22:5S. (Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.)
43. **Conducting clinical trials in private practices: What works and what doesn't.** Ford C. **Abstract:** *Controlled Clinical Trials* 2001; 22:17S. (Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.)
44. **Closeout procedures for clinical trials.** Davis BR. **Abstract:** *Controlled Clinical Trials* 2001; 22:22S. (Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.) (Paper 17)
45. **Follow-up specialist in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis B, Babiak-Vazquez A, deLeon B, Bettencourt J, Nwachuku C. **Abstract:** *Controlled Clinical Trials* 2002; 23:48S. (Presented by S. Pressel at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
46. **The ALLHAT Clinical Trials Center – Expected and unexpected challenges.** Davis BR, Pressel S, Ford C, Piller L, Bettencourt J, Simpson L, deLeon B, Dunn K. **Abstract:** *Controlled Clinical Trials* 2002; 23:56S. (Presented by B.R. Davis at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
47. **Closeout procedures in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis B, Ford C, Bettencourt J, deLeon B, Piller L, Simpson L, Einhorn P, Furberg C, Geraci T, Margolis K, Rahman M, Juratovac A, Feldman S, Kingry C. **Abstract:** *Controlled Clinical Trials* 2002; 23:57S. (Presented by S. Pressel at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
48. **Ascertainment of vital statistics using outside databases in ALLHAT.** Simpson L, Pressel S, Piller L, Bettencourt J, deLeon B, Davis B. **Abstract:** *Controlled Clinical Trials* 2002; 23:76S. (Presented by L. Simpson at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
49. **The review of event reports in ALLHAT.** Piller L, Simpson L, Davis B, Pressel S, deLeon B. **Abstract:** *Controlled Clinical Trials* 2002; 23:77S. (Presented by Linda Piller at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia.)
50. **Baseline characteristics of ALLHAT participants with impaired renal function; association with cardiovascular disease.** Rahman M, Brown C, Coresh J, Eckfeldt J, Jolley M, Kopyt N, Levey A, Pressel S, Reisin E, Walworth C, Davis B and the ALLHAT Collaborative Research Group. **Abstract:** *Am J Hypertension* 2002; 15:175A. (Presented by

- Mahboob Rahman at the 17<sup>th</sup> Annual Meeting of the American Society of Hypertension, New York, NY, May 14-18, 2002.) (Paper 13)
51. **Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Cushman W, Ford CE, Cutler JA, Margolis KL, Davis BR, Bettencourt J, Grimm RH. Abstract: *Circulation* 2002; 106:II-476. (Presented by William Cushman at the 75<sup>th</sup> Annual Scientific Sessions of the American Heart Association, November 17-20 [18th], 2002, Chicago, Illinois.) (Paper 11)
  52. **ALLHAT results and future directions for hypertension research.** Salive ME. (Presented at the American College of Preventive Medicine Meeting, February 22, 2003, San Diego, California.)
  53. **AHT Results.** Wright J. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.) (Final Paper 2)
  54. **Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs. usual care.** Haywood J for the ALLHAT Collaborative Research Group. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.) (Paper 32)
  55. **ALLHAT: Results and implications in older ALLHAT patients.** Williamson J. (Invited presentation at the 9<sup>th</sup> Annual Scientific Sessions of the Society of Geriatric Cardiology, March 29, 2003, Chicago, Illinois.) (Paper 118)
  56. **Cardiovascular disease (CVD) outcomes in hypertensive patients with impaired renal function.** Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group. (Presented by M. Rahman at the National Kidney Foundation 2003 Clinical Meetings, April 2-6, 2003, Dallas, Texas.) (Paper 73)
  57. **Renal outcomes in hypertensive patients with impaired renal function.** Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group. (Presented by M. Rahman at the National Kidney Foundation 2003 Clinical Meetings, April 2-6, 2003, Dallas, Texas.) (Paper 43)
  58. **Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Ford CE, Margolis KL, Piller L, Cushman WC, Wright JT, Colon PJ, for the ALLHAT Collaborative Research Group. (Presented by CE Ford at the 15<sup>th</sup> Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.) (Paper 12)
  59. **Clinical Implications of ALLHAT.** Oparil S. (Presented at the 15<sup>th</sup> Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.)
  60. **The ANBP2 and ALLHAT.** Cutler J, Barrett S. (Presented at the American Academy of Physician Assistants Meeting, May 26, 2003, New Orleans, Louisiana.) (Paper 63)
  61. **ALLHAT - Implications for hypertension in the elderly.** Leenen, F. (Presented at the Canadian Geriatrics Society Annual Meeting, May 30-31, 2003, Ottawa, Canada.)
  62. **ALLHAT.** Alderman M. (Presented at the European Society of Hypertension Meeting, June 13-15 (14), 2003, Milan, Italy.)
  63. **Results of the ALLHAT trial: Antihypertensive trial results by baseline diabetic & fasting glucose status.** Cushman WC, for the ALLHAT Collaborative Research Group. (Presented at the American Diabetes Association Scientific Sessions, June 13-17 [15th], 2003, New Orleans, Louisiana.)
  64. **ALLHAT vs. ANBP2.** Cushman W. (Presented at the Southern Medical Association 7<sup>th</sup> Annual Conference on Hypertension, June 27-29 (28), 2003, Myrtle Beach, South Carolina.)
  65. **Subgroup analysis of blacks and diabetics.** Wright J. (Presented at the National Medical Association Meeting, August 2-7, 2003, Philadelphia, Pennsylvania.)
  66. **ALLHAT and JNC 7.** Probstfield J. (Presented at the European Society of Cardiology Meeting, August 30 - September 3, 2003, Vienna, Austria.)
  67. **ALLHAT Update.** Furberg C. (Presented at Danish Society of Hypertension Meeting, September 25, 2003, Copenhagen, Denmark.)
  68. **Report from ALLHAT.** Wright J. (Presented at AHA Conference on Cardiovascular Science & Healthcare Disparities: The Minority Health Summit 2003, October 3, 2003, Atlanta, Georgia.)
  69. **Cardiovascular disease and renal disease outcomes in hypertensive patients with various levels of baseline renal function.** Rahman M. (Presented at the 2003 Annual Scientific Assembly of the American Academy of Family Physicians, October 1-5 (4th), 2003, New Orleans, Louisiana.) (Paper 43)
  70. **Effects of ACE inhibitor and calcium channel blocker compared with diuretic in high-risk hypertensive person: Further results from**

- ALLHAT.** Hassman J. (Presented at the [American Osteopathic Association American College of Osteopathic Family Physicians Meeting](#), October 14, 2003, New Orleans, Louisiana.)
71. **Metabolic syndrome & hypertension: ALLHAT – What ALLHAT did?** Cushman W. (Presented at the [Consortium for Southeastern Hypertension Control Meeting](#), October 16-18, 2003, Coral Gables, Florida.)
72. **Results from ALLHAT.** Cushman W. (Presented to the [Texas Chapter of the American Society of Hypertension](#), October 18, 2003, Houston, Texas.)
73. **What have we learned from ALLHAT?** Leenen F. (Presented at [Canadian Cardiovascular Congress Meeting](#), October 25-29 (26), 2003, Toronto, Canada.)
74. **Hypertension treatment and diabetes.** Davis BR. (Presented at the [Chilean Society of Internal Medicine Meeting](#), October 28-29, 2003, Santiago, Chile.)
75. **First step therapy for hypertension - ALLHAT.** Davis BR. (Presented at the [Chilean Society of Internal Medicine Meeting](#), October 28-29, 2003, Santiago, Chile.)
76. **Heart failure, LVH, hypertension and treatment.** Davis BR. (Presented at the [Chilean Society of Internal Medicine Meeting](#), October 28-29, 2003, Santiago, Chile.)
77. **ALLHAT: The key findings.** Furberg C. (Presented at the [76th Annual Scientific Sessions of the American Heart Association](#), November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
78. **ALLHAT results for subgroups and secondary outcomes.** Probstfield JL. (Presented at the [76th Annual Scientific Sessions of the American Heart Association](#), November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
79. **After NHANES, ALLHAT and JNC-VII: How can we implement the findings?** Whelton PK. (Presented at the [76th Annual Scientific Sessions of the American Heart Association](#), November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
80. **Atrial fibrillation at baseline and during follow-up in ALLHAT.** Haywood LJ, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. [Abstract: Circulation 2003; 108\(Suppl IV\):IV-371.](#) (Presented by C. Ford at the [76th Annual Scientific Sessions of the American Heart Association](#), November 9-12, 2003, Orlando, Florida.) ([Paper 36](#))
81. **Review of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Heart Failure Validation Study.** Einhorn P, Davis B, Piller L, deLeon B, Simpson L, Kostis J, Levy D, Massie B, Nwachuku C, Black H, Cushman W, for the ALLHAT Collaborative Research Group. [Abstract: Circulation 2003; 108\(Suppl IV\):IV-399-400.](#) (Presented by Paula Einhorn at the [76th Annual Scientific Sessions of the American Heart Association](#), November 9-12, 2003, Orlando, Florida.) ([Paper 56](#))
82. **Incidence of end stage renal disease (ESRD) and cardiovascular disease (CVD) in high risk hypertensive patients with reduced glomerular filtration rate (GFR).** Rahman M. (Presented at the [American Society of Nephrology Meeting](#), November 16, 2003, San Diego, California.) ([Paper 73](#))
83. **ALLHAT: Main results and clinical implications.** Cutler J. (Presented at the [American Society of Health-System Pharmacists Meeting](#), December 9, 2003, New Orleans, Louisiana.)
84. **ALLHAT: Cost-effectiveness analysis and societal implications.** Heidenreich P. (Presented at the [American Society of Health-System Pharmacists Meeting](#), December 9, 2003, New Orleans, Louisiana.) ([Paper 33](#))
85. **Stroke results in ALLHAT.** Oparil S. (Presented at the [29th Annual International Stroke Conference](#), February 5-7, 2004, San Diego, California.) ([Paper 44](#))
86. **New data from ALLHAT.** Alderman M. (Presented at the [International Society of Hypertension Meeting](#), February 15-17, 2004, Sao Paulo, SP, Brazil.)
87. **ALLHAT subgroups – Diabetes, race & renal.** Furberg C. (Presented at the [American College of Cardiology Meeting, Plenary Session](#), March 8, 2004, New Orleans, Louisiana.)
88. **Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: A report from the ALLHAT trial.** Barzilay JI, Pressel S, Davis BR, Margolis KL, Cutler J, Ong ST, Basile J, Sadler LS, Summerson J, Whelton PK. [Abstract: Am J Hypertension 2004; 17:S1.](#) (Presented by Joshua Barzilay at the [19th Annual Meeting of the American Society of Hypertension](#), May 18-22, 2004, New York, NY.) ([Paper 28](#))

89. **Blood pressure control by randomized drug group in ALLHAT.** Cushman WC, Ford CE, Einhorn P, Wright JT, Preston RA, Davis BR, Basile JN. **Abstract:** *Am J Hypertension* 2004; 17:S30. (Presented by Bill Cushman at the 19th Annual Meeting of the American Society of Hypertension, May 18-22, 2004, New York, NY.) (Paper 47)
90. **Results of monotherapy in ALLHAT: On-treatment analyses.** Cutler JA, Piller LB, Pressel S, Graumlich JF, Hamilton BP, Parish DC, Qureshi N, Randall OS, Davis BR. **Abstract:** *Am J Hypertension* 2004; 17:S30-31. (Presented by Jeff Cutler at the 19th Annual Meeting of the American Society of Hypertension, May 18-22, 2004, New York, NY.) (Paper 61)
91. **Diuretics versus ACE inhibitors and calcium channel blockers in the preventing heart failure.** Bavis B. (Invited talk. Presented at the 19th Annual Meeting of the American Society of Hypertension, May 22, 2004, New York, NY.)
92. **Diuretics versus ACE inhibitors and calcium channel blockers in the diabetic patient.** Black H. (Invited talk. Presented at the 19th Annual Meeting of the American Society of Hypertension, May 22, 2004, New York, NY.)
93. **Atrial Fibrillation in ALLHAT.** Haywood J, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. **Abstract:** *Ethnicity and Disease* 2004; 14:???. (Presented by Julian Haywood at the International Society on Hypertension in Blacks Meeting, June 13-16, 2004, Detroit, Michigan.) (Paper 36)
94. **Results of monotherapy in ALLHAT: On-treatment analyses.** Cutler J. **Abstract:** *J of Hypertension* 2004; 22(Suppl 2):S???. (Presented at the European Society of Hypertension Meeting, June 13-17, 2004, Paris, France.) (Paper 61)
95. **Did type of prior antihypertensive therapy influence the heart failure results in ALLHAT?** Grimm R. **Abstract:** *J of Hypertension* 2004; 22(Suppl 2):S151. (Presented at the European Society of Hypertension Meeting, June 13-17, 2004, Paris, France.) (Paper 59)
96. **ALLHAT: Results and implications for older patients.** Williamson J. (Presented at the American Society of Hypertension Carolinas/ Georgia Chapter Meeting, June 26, 2004, Hilton Head, South Carolina.)
97. **Heart failure results in ALLHAT.** Davis B. (Presented at the European Society of Cardiology Scientific Sessions, August 28-September 1, 2004 [8/29], Munich, Germany.) (Paper 46)
98. **Preserved and impaired left ventricular systolic function in ALLHAT.** Kostis J. (Presented at the European Society of Cardiology Scientific Sessions, August 28-September 1, 2004 [9/1], Munich, Germany.) (Paper 52)
99. **Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and normoglycemia.** Thadani T. (Presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.) (Paper 38)
100. **Heart failure results in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Leenen F. (Poster presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.) (Paper 46)
101. **The ALLHAT HF Validation Study: Clinical presentation of hospitalized HF events and subsequent mortality rates.** Einhorn P. (Poster presentation at 77th Annual Scientific Sessions of the American Heart Association, November 7-10, 2004, New Orleans, Louisiana.) (Paper 56)
102. **Clinical outcomes in ALLHAT antihypertensive trial participants with cardiovascular dysmetabolic syndrome.** Davis B. (Presented at 77th Annual Scientific Sessions of the American Heart Association, November 7-10, 2004, New Orleans, Louisiana.) (Paper 48)
103. **Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and normoglycemia.** Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB, Leenen FHH, Louis GT, Margolis K, Mathis DE, Molloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U. **Abstract:** *Southern Medical Journal* 2004; 97(Suppl 1):6. (Oral presentation by Paul Whelton at the 98th Annual Scientific Assembly of the Southern Medical Association, November 11-13, 2004, New Orleans, Louisiana.) (Paper 38)
104. **Outcomes in high-risk hypertensives randomized to CCB vs, ACE inhibitor in ALLHAT.** Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. (Presented by Frans Leenen at 20th Annual Scientific Meeting of the American Society of Hypertension, May 14-18, 2005, San Francisco, CA.) (Paper 78)
105. **Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive persons: The GenHAT Study.** Davis B. (Presented by Barry Davis at 20th Annual Scientific Meeting of

- the American Society of Hypertension, May 14-18, 2005, San Francisco, CA.) (Paper 68 - GenHAT)
106. **Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Piller L, Ford C, Davis B, Nwachuku C, Black H, Oparil S, Gappy S, Retta T, Probstfield J. (Presented by Linda Piller at 20<sup>th</sup> Annual Scientific Meeting of the American Society of Hypertension, May 14-18 [16], 2005, San Francisco, CA.) (Paper 22)
107. **Disseminating clinical trial results: Case study from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Pressel S, Davis B, Bartholomew LK, Cushman W, Whelton P, Nwachuku C. Abstract: *Clinical Trials* 2005; 2(Suppl 1):S37. (Presented by Sara Pressel at the 26<sup>th</sup> Annual Meeting of the Society for Clinical Trials, May 22-25, 2005, Portland, Oregon.)
108. **Use of case-only analysis in clinical trials – rational and example.** Davis BR, Grimm R, Piller L, Cutler J, Margolis K, Barzilay J, Dart R, Graumlich J, Murden R, Randall O, Sawyer K, for the ALLHAT Collaborative Research Group. Abstract: *Clinical Trials* 2005; 2(Suppl 1):S33. (Presented by Barry Davis at the 26<sup>th</sup> Annual Meeting of the Society for Clinical Trials, May 22-25[24th], 2005, Portland, Oregon.) (Paper 57)
109. **Cardiovascular and renal outcomes in patients with diabetes.** Davis B. (Presented at the Blood Pressure Lowering Treatment Trialists' Collaboration Symposium, June 16, 2005, Milan, Italy.)
110. **Cardiovascular outcomes in hypertensives with CHD randomized to amlodipine versus lisinopril in ALLHAT.** Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.) (Paper 78)
111. **Outcomes in high-risk hypertensives randomized to CCB vs. ACE inhibitor in ALLHAT.** Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.) (Paper 78)
112. **Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive persons: The GenHAT Study.** Davis B. (European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.) (Paper 68 - GenHAT)
113. **Clinical outcomes in participants with metabolic syndrome in ALLHAT.** Black H, Davis B. (Presented by Henry Black at European Society of Hypertension Scientific Sessions, June 17-21[19], 2005, Milan, Italy.) (Paper 48)
114. **Clinical outcomes by race in non-diabetic participants with cardiovascular dysmetabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Wright JT Jr, Davis BR, Black HR, for ALLHAT Collaborative Research Group. (Oral presentation by Jackson Wright at International Society of Hypertension In Blacks, July 15-19, 2005, San Juan, Puerto Rico.) (Paper 48)
115. **Race paper–Not sure if Jackson made two presentations at ISHIB????** Wright J, (National Medical Association, July 23-28, 2005, New York, NY) (Paper 37)
116. **Clinical outcomes by race in non-diabetic participants with cardiovascular metabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** Wright J, (National Medical Association, July 23-28, 2005, New York, NY) (Paper 48)
117. **The relation of hypokalemia at 1 year to morbidity and mortality: the ALLHAT experience.** Alderman MH, Piller LB, Ford CE, Davis BR, Einhorn P, Cushman W, Calhoun D, Eckfeldt J, Franklin S, Furberg C, Ong S, Oparil S, Papademetriou V, Probstfield J. (Presented by Jeff Probstfield at the European Society of Cardiology Congress 2005, September 3-7[7th], 2005, Stockholm, Sweden.) (Paper 24)
118. **Stroke results: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Oparil S, Davis B, Nwachuku C, Pressel S, Alderman M, Calhoun D, Cushman W, Cutler C, Ellsworth A, Fendley H, Franklin S, Habib G, Leenen F, Probstfield J, Sastrasinh S, for the ALLHAT Research Group. (Presented by Susan Oparil at the 78<sup>th</sup> Annual Scientific Sessions of the American Heart Association, November 13-16 [14], 2005, Dallas, Texas.) (Paper 44)
119. **Activism to promote health of patients and the public.** Katz (Presented by Katz at 29<sup>th</sup> Annual Meeting of the Society of General Internal Medicine, April 26-29, 2006, Los Angeles, California.) (ALLHAT Dissemination)
120. **Racial differences in pravastatin versus usual care.** Margolis K. (Presented by Karen Margolis at the HMO Research Network Meeting, May 1-3, 2006, Cambridge, Massachuset.) (Paper 39)

121. **Influence of atrial fibrillation on incidence and outcome of stroke in ALLHAT.** Abstract: *Circulation* 2006; 113(21): e807-e807. (Poster; Presented by Julian Haywood at 7<sup>th</sup> Scientific Forum on Quality Care and Outcomes Research in Cardiovascular Disease and Stroke, May 7-9, 2006, Washington, D.C.) (Paper 36)
122. **Retrospective analysis of ALLHAT: Current views.** (Invited presentation by Jackson Wright at American Society of Hypertension symposium on Hypertension in the African American Population, May 16, 2006, New York, New York.)
123. **Metabolic results in hypertension trials.** (Presented by Barry Davis, Invited speaker in debate with Mark Houston at 21<sup>st</sup> Annual Scientific Meeting of the American Society of Hypertension, May 17-20, 2006, New York, New York.)
124. **Influence of atrial fibrillation on incidence and outcome of stroke in ALLHAT.** Haywood J, Ford C, Crow R, Davis B, Massie B, Einhorn P, Williard A, Nwachuku C for the ALLHAT Investigators. Abstract: *J Clin Hypertens* 2006; 8(Suppl A): A5-A5. (Presented by Julian Haywood at 21<sup>st</sup> Annual Scientific Meeting of the American Society of Hypertension, May 17-20, 2006, New York, New York.) (Paper 36)
125. **Are angiotensin converting enzyme inhibitors and/or calcium channel blockers superior to diuretics in preventing development of or revascularization for angina or peripheral vascular disease? Insights from the ALLHAT trial.** Basile JN, Courtney DL, Dart R, Einhorn PT, Ellsworth AJ, Fendley HF, Furberg CD, Habib GB, Leenen FHH, Piller LB, Rahman M, Simpson L, Whelton PK. (Presented by Gabriel Habib at the European Society of Hypertension Meeting, June 12-15, 2006, Madrid, Spain.) (Paper 45)
126. **Clinical outcomes by race in participants with the metabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial on doxazosin vs chlorthalidone.** Wright JT, Davis BR, Haywood J, Einhorn P, Pressel S, for the ALLHAT Collaborative Research Group. (Presented by Jackson Wright at the International Society on Hypertension In Blacks Meeting, June 23-26, 2006, Atlanta, Georgia.) Oral and poster presentation. (Paper 91)
127. (Presented by Terri Geraci at American Academy of Nurse Practitioners, June 20-24, 2006, Grapevine, Texas.)
128. **Megatrials: ALLHAT.** Davis BR. (Invited presentation by Barry Davis at American Statistical Association Meeting, August 6-10, 2006, Seattle, Washington.)
129. **Relationship of 1 year hypokalemia incidence to clinical outcomes in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Alderman M, Calhoun D, Cushman W, Davis B, Eckfeldt J, Einhorn P, Ford C, Franklin S, Furberg C, Ong S, Oparil S, Papademetriou V, Piller L, Probstfield J. (Presented by Michael Alderman at 79<sup>th</sup> Annual Scientific Sessions of the American Heart Association, November 12-15, 2006, Chicago, Illinois.) (Paper 24)
130. **Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT?** Grimm R, Davis B, Cutler J, Piller L, Margolis M, Barzilay J, Dart R, Graumlich J, Murden R, Randall O, for the ALLHAT Collaborative Research Group. (Poster presented by Richard Grimm at American College of Cardiologist Meeting, March 25, 2007, New Orleans, Louisiana.) (Paper 59)
131. **Management of high blood pressure in clinical practice: Perceptible qualitative differences in approaches used by clinicians.** Nwachuku CE, Bastien A, Morgan D, Cutler JA, Grob G, Margolis K, Roccella EJ, Pressel S, Davis BR, Caso M, Sheps S, Weber M. (Presented by Ed Roccella at 22<sup>nd</sup> Annual Scientific Meeting of the American Society of Hypertension, May 19-22, 2007, Chicago, Illinois.) (Paper 67)
132. **Implications of metabolic effects, diabetes incidence and CVD risk, outcomes in MetS.** Wright JT Jr, for the ALLHAT Collaborative Research Group. (Presented by Jackson Wright at 22<sup>nd</sup> Annual Scientific Meeting of the American Society of Hypertension, May 19-22, 2007, Chicago, Illinois.) (Papers 48 & 91)
133. **Design and Analysis of a Cost-Effectiveness Study within a Large, Simple Trial: The ALLHAT Trial.** Davis BR, Heidenreich PA, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel S, Nwachuku C, Goldman L. Abstract: *Clinical Trials* 2007; 4:439-439. (Presented by Barry Davis at 28<sup>th</sup> Meeting of the Society for Clinical Trials, May 20-23, 2007, Montreal, Canada.) (Paper 33)
134. **Impact of the publication of the major outcomes of ALLHAT and the JNC-7 report on prescriptions filled by newly diagnosed patients with hypertension.** Muntner P, Krousel-Wood M, Hyre AD, Erin Stanley E, Cushman W, Cutler JA, Piller L, Goforth G, Whelton PK. Abstract: *J Clin Hypertension* 2008; 10(Suppl A):A123-A123. (Presented by Paul Muntner at the 23<sup>rd</sup> Annual Scientific Meeting and Exposition of the American Society of Hypertension, May 14-17, 2008, New Orleans, Louisiana.) (Paper 110)

135. **Major secondary outcomes in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** Piller LB, Simpson LM, Habib GB, Rahman M, Basile J, Courtney DL, Dart R, Einhorn P, Ellsworth A, Fendley H, Leenen FRH, Morrison D, Whelton PK. **Abstract:** [J Clin Hypertension 2008; 10\(Suppl A\):A125-A125.](#) (Presented by Linda Piller at the [23rd Annual Scientific Meeting and Exposition of the American Society of Hypertension](#), May 14-17, 2008, New Orleans, Louisiana.) ([Paper 45](#))
136. **ALLHAT findings revisited 5 years later in the context of subsequent analyses.** Probstfield JL, Wright JT, Einhorn PT, Pressel S, Davis BR, for the ALLHAT Investigators. (Presented by Jeff Probstfield at the [European Society of Cardiology Congress 2008](#), August 30-September 3, 2008, Munich, Germany.) ([Paper 92](#))
137. **Cardiovascular Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care stratified by baseline glomerular filtration rate (GFR): A report from ALLHAT-LLT.** Huml A, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasin S, Stanford C, Rahman M. (Poster presented Nov. 6 by Mahboob Rahman at the [2008 American Society of Nephrology Annual Meeting](#), November 4-9, 2008, Philadelphia, Pennsylvania.) ([Paper 121](#))